Drug
Fosaprepitant clinical trials
Also written MK-0517.
- studies test it
- 38
- open now
- 3
- in phase 3
- 9
- first study started
- 2005
Keep track of what changes. Save the fosaprepitant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
38 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 2 |
| 2015 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 7
- Phase 2
- 10
- Phase 3
- 9
- Phase 4
- 5
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it.
- Nausea
- 10
Who runs them
Industry 12 · Other 26
Merck Sharp & Dohme LLC (12) · Sun Yat-sen University (2) · Montefiore Medical Center (2) · Shanghai Children's Medical Center (2) · Alliance for Clinical Trials in Oncology (1) · Shantou University Medical College (1) · Stanford University (1) · Philip Philip (1)
Often tested with
Tested in the same studies.
Aprepitant (8) · Dexamethasone (5) · Ondansetron (4) · Palonosetron (2) · 5-Hydroxytryptamine Receptor 3A (1) · Ifosfamide (1) · Granisetron Transdermal Patch (1) · Cisplatin (1)
Studies
Open first, then newest update. How each study uses fosaprepitant is read from its arms, and is right about nine times in ten.
Testing it · 38
- Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and MetoclopramideNot yet recruitingPhase 4Montefiore Medical CenterNCT06740812Written as Fosaprepitant for Injection
- Antiemetic Fosaprepitant To Remedy Nausea and VomitingRecruitingPhase 2/3Montefiore Medical CenterNCT06382012Written as Fosaprepitant 150 mg
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV PreventionEnrolling by invitationNot applicableSamsung Medical CenterNCT05773950Written as fosaprepitant
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyCompletedPhase 3Alliance for Clinical Trials in OncologyNCT03578081Written as Fosaprepitant Dimeglumine
- Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)CompletedPhase 4Merck Sharp & Dohme LLCNCT04054193Written as Fosaprepitant Dimeglumine
- Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal CancerCompletedPhase 3Shantou University Medical CollegeNCT05564286Written as Fosaprepitant
- Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric PatientsCompletedPhase 2Sun Yat-sen UniversityNCT04508400Written as Fosaprepitant,ondansetron, dexamethasone
- Low Dose Aprepitant for Patients Receiving CarboplatinTerminatedPhase 2Albert Einstein College of MedicineNCT03237611Written as Fosaprepitant 115 MG
- Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic SurgeryStatus unknownNot applicableQilu Hospital of Shandong UniversityNCT05881486Written as Fosaprepitant 150 mg
- Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.Status unknownNot applicableXijing HospitalNCT05755659Written as Fosaprepitant Dimeglumine for Injection
- Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedPhase 1Sun Yat-sen UniversityNCT04636632Written as fosaprepitant
- Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain InjuryWithdrawnEarly Phase 1Arun GuptaNCT03035838Written as Fosaprepitant
- Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General AnesthesiaCompletedPhase 4Stanford UniversityNCT03197064Written as Fosaprepitant 150 mg
- Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic DrugsStatus unknownNot applicableShanghai Children's Medical CenterNCT05230654Written as Fosaprepitant
- Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner PatientsStatus unknownNot applicableShanghai Children's Medical CenterNCT04873284Written as fosaprepitant
- Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination ChemotherapyCompletedNot applicablePhilip PhilipNCT01504711Written as fosaprepitant dimeglumine
- Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI TrialCompletedNot applicableMulticenter Clinical Study Group of Osaka, Colorectal Cancer Treatment GroupNCT01344304Written as Aprepitant / Fosaprepitant
- Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)CompletedPhase 2Merck Sharp & Dohme LLCNCT01697579Written as Fosaprepitant
- Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)TerminatedPhase 3Merck Sharp & Dohme LLCNCT02519842Written as Fosaprepitant
- PALONOSETRON X FOSAPREPITANT IN PONVStatus unknownPhase 4Hospital Federal de BonsucessoNCT03586817Written as Fosaprepitant
See all 38 studies that test fosaprepitant →
Given in every arm · 4 — fosaprepitant is usual care beside what is tested
- Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing RegimenRecruitingPhase 3The Affiliated People's Hospital of Ningbo UniversityNCT07413809Written as Fosaprepitant
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HECCompletedPhase 3Heron TherapeuticsNCT02106494Written as Fosaprepitant
- Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple MyelomaCompletedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT02780609Written as Fosaprepitant
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINVStatus unknownPhase 3Fudan UniversityNCT04912271Written as Fosaprepitant
As the comparator · 5 — what is tested is compared with fosaprepitant
- Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)RecruitingPhase 2Helsinn Healthcare SANCT06904235Written as Reference Treatment: IV fosaprepitant infusion
- An Relative Bioavailability Study of BH006 for Injection in Healthy SubjectsNot yet recruitingEarly Phase 1Zhuhai Beihai Biotech Co., LtdNCT06427681Written as Fosaprepitant for injection+Palonosetron hydrochloride injection
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05841849Written as Fosaprepitant
- Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving ChemotherapyTerminatedPhase 2M.D. Anderson Cancer CenterNCT02732015Written as Fosaprepitant Dimeglumine
- Dose-finding Study of APD403 to Prevent Nausea and Vomiting After ChemotherapyCompletedPhase 2Acacia Pharma LtdNCT01857232Written as Fosaprepitant
Codes
What other systems call fosaprepitant · ClinicalTrials.gg INT006261
- MeSH (NLM) C579707fosaprepitantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6L8OF9XRDCFOSAPREPITANTConfirmed FDA, NLM, Wikidata
- RxNorm 1731071Confirmed FDA, Wikidata
- Wikidata Q5473324fosaprepitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72787FosaprepitantOne source FDA
- DrugBank DB06717One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579707 | fosaprepitant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6L8OF9XRDC | FOSAPREPITANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1731071 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5473324 | fosaprepitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72787 | Fosaprepitant | One source FDA |
| DrugBank | DB06717 | — | One source Wikidata |
Also registered as fosaprepitant dimeglumine (UNII D35FM8T64X · RxNorm 754763).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.